Corteva and Globachem Agree to Crop Protection Joint Venture Ahead of Spinoff

Corteva and Belgium's Globachem N.V. have signed a definitive agreement to establish a 50/50 joint venture focused on developing and commercializing crop protection products for farmers across Europe and the Americas, according to reporting by Yahoo Finance . The partnership comes as Corteva prepares to spin off its crop protection division into an independent publicly traded company, named Vylor, on October 1.

The joint venture builds on an established multi-year commercial relationship between the two businesses. Under the agreement, Corteva will contribute late-pipeline and commercial-stage technology alongside discovery and development capabilities. Globachem, a privately held Belgian crop protection marketer, brings expertise in formulation chemistry and regulatory execution. The joint venture will operate as an independent entity, with resulting products eligible for commercialization by either parent company or both.

The agreement follows mixed financial results across the first half of 2026. For the six-month period, Corteva reported net sales up 4% to $11.28 billion and operating earnings before interest, taxes, depreciation, and amortization (EBITDA) up 10% to $3.70 billion. Within Crop Protection specifically, sales volumes rose 2% on demand for new products, lifting segment operating EBITDA by 9% to $776 million despite negative pricing trends.

Second-quarter figures showed quarterly deceleration. Corteva's net sales in the second quarter slipped 1% year-over-year to $6.38 billion, organic sales fell 2%, and income from continuing operations declined 12% to $1.22 billion, driving GAAP earnings per share down 10% to $1.81. While quarterly operating EBITDA grew, the divergence between GAAP net income and non-GAAP operational metrics reflected margin and accounting friction.

Pricing challenges remain concentrated in Crop Protection, where realized prices dropped 3% in the first half and 4% in the second quarter, driven by competitive market dynamics in Latin America. Favorable currency movements and unit volume growth partially countered the decline. The Globachem joint venture offers no near-term relief for these pricing pressures, as product introductions from the collaboration are not anticipated until the early 2030s.

The joint venture transaction is targeted to close in the fourth quarter of 2026, subject to customary regulatory approvals. Concurrently, Corteva is navigating the operational costs of its corporate separation, having already factored a $25 million timing headwind into its full-year guidance. Public market positioning remains stable ahead of the October 1 split: hedge fund holders rose from 48 to 53 in the latest quarter, short interest stood at 3.05% of float, and the stock traded at a forward price-to-earnings ratio of 19.16 as of September 18.